Form 4 for KPTI Karyopharm Therapeutics Inc.
Accepted 2025-10-16 00:00:00 ET · period of report 2025-10-15 · accession 0001193125-25-241484 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-16 | 2025-10-15 | KPTI | Poulton Stuart | EVP, Chief Development Off | A - Grant | $0.00 | +39.7K | 67.4K | +143% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-15 | A | A | 39,682 | $0.00 | 67,392 | D | — | — | (F1) Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on December 31, 2026. |